 |
answer text |
<p>The Department fully understands that maintaining access to hormone replacement
therapy (HRT) medications is vitally important to many people in this country.</p><p>We
are aware of ongoing supply issues with some HRT transdermal patches due to manufacturing
issues. We have been working closely with all suppliers of HRT transdermal patches
to maintain overall supply to patients. Although some HRT transdermal patches are
affected by supply issues, supplies of other alternative HRT transdermal patches have
remained available.</p><p>We continue to work with all stakeholders to ensure relevant
information about the HRT products affected by supply issues and the products that
remain available is shared across the National Health Service on a regular basis.
We have already issued comprehensive communications to the NHS with regard to availability
and signposted clinicians to sources they can use to support local decision making
around switching patients who are affected by the current supply disruptions.</p><p>
</p><p>We will continue to work directly with all suppliers of the affected and alternative
products to resolve the supply issues as soon as possible and ensure supplies of HRT
products including transdermal patches continue to remain available.</p><p><strong>
</strong></p><p>There is no evidence that the small number of current HRT supply issues
we are managing are related to EU exit or increasing because of this.</p><p><strong>
</strong></p>
|
|
